Cancer Tissue Diagnostics market in Europe is expected to grow from US$ 512.73 Mn in the year 2018 and is expected to reach US$ 830.28 Mn by 2027 growing at a CAGR of 5.8% over the forecast period.
The growth of the market is driven by the factors such as increasing number of cancer cases and rising geriatric population. On the other hand, high cost of cancer diagnostics in some of the European countries is limiting the growth of market is likely to have a negative impact on the growth of the market in the coming years.
Cancer is among the leading cause of deaths across Europe globe and is profoundly affecting the quality of life. Thus, cancer will be a burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Additionally, cancer is found to be commonly prevalent in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in the UK were due to cancer.
The World Health Organization (WHO) also reported that with over 3.7 million new cases and 1.9 million deaths each year, cancer is the second most important cause of morbidity and death in Europe. Moreover, Europe comprises of one-eighth of the total world population, however approximately a quarter of global cancer cases with 3.7 million new patients are from Europe, suggesting high incidence rate of cancer in the region. Furthermore, the data also suggests that 40% of these cancer cases are preventable with appropriate diagnosis at early stages and correct treatment and medication.
The Spain Cancer Tissue Diagnostics market is expected to grow at highest rate during the forecast period owing to various cancer research studies undergoing in the country, increasing number of cancer patients in the country, and various solutions undertaken to reduce the financial burden due to cancer on the country. Moreover, the country also is the fastest growing among other European countries owing to the increasing medical tourism flourishing in Spain.
Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
EUROPE CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION
By Test Type
- Immunohistochemical Tests
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
- In Situ Hybridization Tests
- Breast Cancer
- Lung Cancer
- Bladder Cancer
- Others
By Country
- France
- Germany
- UK
- Italy
- Spain
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher
- Abcam plc.
Europe Cancer Tissue Diagnostics Report Scope
Report Attribute | Details |
---|---|
Market size in 2018 | US$ 512.73 Million |
Market Size by 2027 | US$ 830.28 Million |
Global CAGR (2019 - 2027) | 5.8% |
Historical Data | 2016-2017 |
Forecast period | 2019-2027 |
Segments Covered |
By Test Type
|
Regions and Countries Covered | Europe
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset



Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Test Type, and Country

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
UK, Germany, France, Italy, Russia
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Europe Cancer Tissue Diagnostics Market
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher
- Abcam plc.